The European Medicines Agency (EMA) has warned that the analogous drugs of LPG1, such as Ozempic, intended to treat type 2 diabetes, should not be used for aesthetic weight loss in people without obesity or health problems related to overweight.
The EMA urges health professionals to advise these people about maintaining a healthy lifestyle instead of resorting to medications not intended to lose weight.The growing demand for these drugs has caused shortage in the EU, affecting those who really need them.
The director of the EMA, Emer Cooke, stressed that the supply cannot follow the rhythm of the demand since 2022, and the situation will not be resolved in 2024. The EMA asks all those involved, including industry, health and public, collaborating toSolve scarcity.
In addition, EMA emphasizes that the improper use promoted in social media and networks has aggravated scarcity.He also warned about the risk of counterfeit products and asked citizens to buy these medications only with recipe and in registered pharmacies.
The agency urged pharmacists to ensure that their advertising messages are approved by regulatory authorities and implement awareness campaigns on weight management and current scarcity.
GLP1 medications are indicated in the EU only for diabetes, except saxenda and wegovy, which are for the management of weight in people with obesity or related health problems.Mounjaro, available in Spain since July 1, is authorized for both uses under certain conditions.
Finally, the EMA recalled the possible side effects of these medications, such as digestive problems, and explained how LPG1 analogues help control blood glucose levels and regulate appetite.
